Influenza vaccine quadrivalent - Abbott Biologicals

Drug Profile

Influenza vaccine quadrivalent - Abbott Biologicals

Alternative Names: QIV-Abbott-Biologicals; Quadrivalent influenza vaccine - Abbott Biologicals; Quadrivalent-influenza-vaccine-surface-antigen-inactivated-Abbott-Biologicals

Latest Information Update: 25 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Abbott Biologicals BV
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Influenza virus infections

Most Recent Events

  • 14 Jul 2017 Abbott Biologicals completes a phase III trial in Influenza virus infections (Prevention, In children, In adolescents) in Lithuania, Finland, Germany and Hungary (IM) (EudraCT2015-005482-23)
  • 06 Jun 2017 Phase-III clinical trials in Influenza virus infections (Prevention, In children, In infants) in Denmark (IM) (EudraCT2016-004904-74)
  • 11 Jul 2016 Phase-III clinical trials in Influenza virus infections (Prevention, In children, In adolescents) in Lithuania (IM) (EudraCT2015-005482-23)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top